Thecosystems Breast Cancer
See the most influential people, bodies and activities in breast cancer today. Understand their relevance and their connections. Explore their profiles, and engage them with confidence. Thecosystems contain the information you’d find yourself, and so much more. Checked, concise, current, and easy-to-navigate.
Why subscribers choose Thecosystems Breast Cancer
Across the world academics, physicians, policy makers, economists, even patients are working on how to prevent, detect, and treat breast cancer.
- How can you be sure you’re talking to the people who are most likely to be interested in your drug, device or service?
- How can you assess their influence and their expertise?
- How can you connect with them?
- And when you do, how do you prepare so that you plan effectively and engage confidently?
A subscription to Thecosystems Breast Cancer helps you at every stage, with information that’s up-to-date, accurate and comprehensive. Available online, on your mobile, tablet, laptop, and desktop, by annual subscription. And because we guarantee that all the data in each Thecosystem has been double-checked, you’re safe to use it with colleagues, contacts and customers.
Get the big picture
360o perspective and map of connections, wherever they are in the world and whatever their role or level of expertise. Don’t miss out on the rising stars!
Use Thecosystems deep profiles to select your targets, understand their background, specialisms and interests, and plan your communications thoroughly.
Read around the subject
What have they published, where have they spoken, what are their plans, who are their collaborators? And what else is going on?
The more you know, the better the conversation.
See how everything connects
All the information you need, in one place.
Up to date and instantly useful.
Over 4500 experts
- Find profiles of thousands of the experts actively shaping breast cancer
- Explore professional networks
- Academics, physicians, policy makers, economists, even patients
- High-quality information and insights traditionally reserved for senior executives
- Accurate, complete, up-to-date, referenced and connected
Over 100 including:
- NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
- 3rd International Consensus Guidelines for Advanced Breast Cancer (ABC3)
- National consensus in China on diagnosis and treatment of patients with advanced breast cancer
- AIOM Guidelines 2018 BREAST NEOPLASMS
Regulatory & Reimbursement Organisations
- U.S. Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- Health Canada, Health Products and Food Branch (HPFB)
- College ter Beoordeling van Geneesmiddelen (CBG)
- National Institute for Health and Care Excellence (NICE)
Over 100 including:
- American Society of Clinical Oncology (ASCO)
- Japanese Breast Cancer Society
- European Society for Medical Oncology (ESMO)
- Japanese Society of Medical Oncology (JSMO)
- American Association for Cancer Research (AACR)
Patient Advocacy Groups
Over 160 including:
- Brustkrebs Deutschland e.V.
- Europa Donna
- National Breast Cancer Coalition
- Susan G Komen Breast Cancer Foundation
Over 750 including:
- Breast cancer research : BCR
- Breast cancer (Tokyo, Japan)
- CA: a cancer journal for clinicians
- Annals of oncology : official journal of the European Society for Medical Oncology
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Over 550 including:
- 2019 Global Breast Cancer Conference
- 2019 San Antonio Breast Cancer Symposium
- 2019 ESMO Breast Cancer
- 2019 Brazilian Breast Cancer Symposium
- 2018 Annual Meeting of American Society of Clinical Oncology (ASCO)
Over 1400 including:
- Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
- Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
- A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
- The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
Thecosystems Breast Cancer